The Institute is recognized by the National Cancer Institute (NCI) as one of only 47 Comprehensive Cancer Centers in the U.S. This designation signifies that all research, treatment and educational programs meet rigorous national standards and that the Institute has contributed fundamentally to the fight against cancer.
RPCI is also a member of the National Comprehensive Cancer Network (NCCN), an alliance of the nation's leading cancer centers. A not-for-profit organization, the NCCN brings together the best minds in science to engineer continuous quality improvements in cancer care, improves the effectiveness of cancer care delivery through the ongoing collection and analysis of outcome data on a national basis, enhances communications and collaboration among member institutions, offers access to the latest, most promising clinical trials, and provides best practice guidelines and measurement tools.
Roswell Park has achieved accreditation from the The Joint Commission (TJC) as a result of its demonstrated compliance with TJC's nationally recognized health care standards.
The innovative quality of our faculty’s research has earned RPCI a place among the National Cancer Institute’s top grantees.
- Over the past century, RPCI has been the source of historic breakthroughs in the field of oncology.
- RPCI initiated the nation’s first chemotherapy research program.
- RPCI conducted some of the earliest studies linking smoking to lung cancer.
- RPCI developed the PSA test for prostate-cancer screening.
- RPCI developed photodynamic therapy (PDT), approved by the FDA for the treatment of esophageal cancer and non-small cell lung cancer, and precancerous lesions in patients with Barrett's esophagus. RPCI is now developing the second generation of PDT drugs.
- RPCI geneticists created the gene library used to map and sequence the human genome. An RPCI geneticist was part of the research team involved in the international effort.